http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
오늘 본 자료
김창연,이진식,김종구,이계현,손경락,김병준 대한산부인과학회 1994 Obstetrics & Gynecology Science Vol.37 No.6
저자들은 본 병원 산부인과에서 정상임신중에 발생한 Hyperreactio Luteinalis 1례를 경험하였기에 간단한 문헌고찰과 함께 이를 보고하는 바이다. Hyperreactio Luteinalis refers to moderate to marked cystic enlargement of the ovaries due to multiple benign theca lutein cysts and is most often associated with hydatidiform mole or choriocarcinoma. We present a case of hyperreactio luteinalis unassociated with trophoblastic disease and review the literature. This case, 28-year old primigravida, was admitted to our hospital due to lower abdominal pain and increasing dyspnea. By ultrasonography, which was conducted because of uncertain gestatinal criteria, there was a single fetus and a normal-appearing placenta; the dimensions of the biparietal diameter and femur length were consistent with those of a 16-week gestation; also, bilateral multicystic adnexal masses were found (right, 19*11*14 cm; left, 15*10*17 cm). After bilateral wedge resection of the ovaries conservative treatment was done. A healthy 2900 g female infant was delivered in the 37th week of pregnancy. Pathologically theca lutein cysts were confirmed.
Preclinical evaluation of sorafenib-eluting stent for suppression of human cholangiocarcinoma cells
Kim, Do Hyung,Jeong, Young-Il,Chung, Chung-Wook,Kim, Cy Hyun,Kwak, Tae Won,Lee, Hye Myeong,Kang, Dae Hwan Dove Medical Press 2013 INTERNATIONAL JOURNAL OF NANOMEDICINE Vol.8 No.-
<P><B>Background</B></P><P>Cholangiocarcinoma is a malignant tumor arising from the epithelium of the bile ducts. In this study, we prepared sorafenib-loaded biliary stents for potential application as drug-delivery systems for localized treatment of extrahepatic cholangiocarcinoma.</P><P><B>Methods</B></P><P>A sorafenib-coated metal stent was prepared using an electrospray system with the aid of poly(ɛ-caprolactone) (PCL), and then its anticancer activity was investigated using human cholangiocellular carcinoma (HuCC)-T1 cells in vitro and a mouse tumor xenograft model in vivo. Anticancer activity of sorafenib against HuCC-T1 cells was evaluated by the proliferation test, matrix metalloproteinase (MMP) activity, cancer cell invasion, and angiogenesis assay in vitro and in vivo.</P><P><B>Results</B></P><P>The drug-release study showed that the increased drug content on the PCL film induced a faster drug-release rate. The growth of cancer cells on the sorafenib-loaded PCL film surfaces decreased in a dose-dependent manner. MMP-2 expression of HuCC-T1 cells gradually decreased according to sorafenib concentration. Furthermore, cancer cell invasion and tube formation of human umbilical vein endothelial cells significantly decreased at sorafenib concentrations higher than 10 mM. In the mouse tumor xenograft model with HuCC-T1 cells, sorafenib-eluting PCL films significantly inhibited the growth of tumor mass and induced apoptosis of tumor cells. Various molecular signals, such as B-cell lymphoma (Bcl)-2, Bcl-2-associated death promoter, Bcl-x, caspase-3, cleaved caspase-3, Fas, signal transducer and activator of transcription 5, extracellular signal-regulated kinases, MMP-9 and pan-janus kinase/stress-activated protein kinase 1, indicated that apoptosis, inhibition of growth and invasion was cleared on sorafenib-eluting PCL films.</P><P><B>Conclusion</B></P><P>These sorafenib-loaded PCL films are effective in inhibiting angiogenesis, proliferation and invasion of cancer cells. We suggest that sorafenib-loaded PCL film is a promising candidate for the local treatment of cholangiocarcinoma.</P>
김승조,이헌영,김창이,김수평,김진홍,나덕진,신종철,이종승 대한산부인과학회 1994 Obstetrics & Gynecology Science Vol.37 No.5
저자들은 반복적 태아 손실이 있는 부부에서 조직적합성의 연관성 정도를 규명하고, 면역학적 원인으로 진단된 반복적 태아 손실 환자에 대한 면역치료시 그 치료 기준을 새롭게 정하기 위해 HLA class I항원에 대해서는 혈청학적인 방법으로 HLA class II항원에 대해서는 최근에 개발된 이중 PCR법을 이용하여 HLA항원의 발현 빈도, 동형접합성, 부동성 및 공유도를 조사하여 다음과 같은 결과를 얻었다. 1. HLA class I의 유전자 발현 빈도는 환자군에서 Cw3, A2, Cw1, A24, B22등의 순으로 높았으며, 대조군에 비해 B17, B61, Cw1 및 Cw3의 발현빈도가 통계적으로 유의하게 높았다(p=0.006), p=0.004, p=0.006, p=0.001). 2. HLA class II의 유전자 발현 빈도는 환자군에서 DQB1*1, DQA*03, DPB1*02, DPB1*05, DQA1*01, DRB1*04, DRB1*06, DRB1*08등의 순으로 높았으며, 대조군에 비해 DRB1*08, DQA1*06 및 DPB1*13등의 발현 빈도가 통계적으로 유의하게 높았다(P=0.03, P=0.001, P=0.001). 3. 동형접합성 빈도는 DRB1 및 DPB1 유전자 좌에서 환자군이 대조군에 비해 통계적으로 유의하게 높았다(P=0.02, P=0.001). 반면에 P 유전자 좌에서는 환자군이 대조군에 비해 유의하게 높았다( p=0.002). 4. 반대로, 부동성 정도는 DRB1 및 DPB1 유전자좌에서 환자군이 대조군에 비해 통계적으로 유의하게 낮았으며(P=0.029, P=0.013), B유전자 좌에서는 환자군이 대조군에 비해 유의하게 높았다(P=0.016). 5. 각 유전자 좌에서의 공유 빈도는 C유전자 좌에서만 환자군이 대조군에 비해 통계적으로 유의하게 높았지만(P=0.037), 나머지 모든 유전자 좌에서도 환자군이 대조군에 비해 비교적 높은 공유 빈도를 보이고 있다. 6. HLA유전자 좌를 4개 이상 공유하고 있는 부부와 5개 이상 공유하고 있는 부부의 빈도는 각각 환자군이 대조군에 비해 현저히 높았다(P=0.042, P=0.015). 반면에 HLA유전자 좌를 3개 이상 공유하고 있는 부부의 빈도는 두 군사이에 통계적으로 유의하지 않았다(P=0.051). 이상의 결과로 보아 저자들은 반복적 태아 손실 조직 적합성과는 비교적 밀접한 관계가 있으며, 특히 HLA class II유전자 좌가 HLA class I유전자 좌보다 더 밀접한 관계가 있음을 관찰하였다. 또한 부부 사이에 공유하는 HLA 유전자 좌의 수가 적어도 4개 이상 되어야 면역요법 대상이 될 것으로 생각된다. 앞으로 HLA 유전자 형벌법을 면역요법에 이용하면 부적합성을 보이는 임파구만 선택적으로 사용할 수 있을 것으로 기대된다. The survival or loss of the fetus as an allograft remains a significant immunological problem. Although chromosomal abnormality has been known as the major cause in spontaneous abortion, immunologic factors have recently been reported as the major cause in recurrent pregnancy loss(RPL). Many studies have supported the association between HLA antigens and RPL, but other studies could not confirm this finding. The purpoe of this study is to clarify these conflicting results and determine the new criteria of immunotherapy in couples with RPL due to immunologic causes. To clarify the relationship between HLA antigens and RPL, incidence of hla antigens, homozygosity, degree of disparity and incidence of sharing from 25 couples experiencing RPL were compared with those of 51 randomized fertile couples as a control group. Tissue typing was performed using a standard microlymphocytotoxictiy test for HLA class I(A,B & C) and a new method of two step polymerase chain reaction(PCR) of DNA samples followed by gel electrophoresis for HLA class II (DRB1, DQA1, DQB1 & DPB1). The results were as follows: 1. In HLA class I antigens, there relatively increased the incidences of Cw3, A2, Cw1, A24 & B22 in RPL group. And compared with the control group, there were significantly more incidences of B17, B61, Cw1 & Cw3. 2. In HLA class II, there relatively increased the incidences of DQB1*01, DQA1*03, DPB1*2, DPB1*05, DQA1*01, DRB1*04, DRB1*06 & DRB1*08 in RPL group. And compared with the control group, there were significantly more incidences of DRB1*08, DQA1*06 & DPB1*13. 3. There were significantly more incidences of homozygosity at the DRB1 & DPB1 loci in RPL group compared with the control group. On the other hand, there were significantly less incidences at the B locus in RPL group. 4. By contrast, the degree of disparity significantly decreased at the DRB1 & DPB1 loci and significantly increased at the B locus in RPL group compared with the control group. 5. Incidence at individual locus significanly increased only at the C locus in RPL group compared with the control group. But all of the remaining loci tended to increase relatively in RPL group. 6. incidence of couples with HLA alleles shared four or more was significantly increased in RPL group compared with the control group. And incidence of couples shared five or more was also significantly increased in RPL group. But incidence of couples with HLA alleles shared three or more was not significantly different between two groups. The findings of this study suggest that it seems to me relatively close association between RPL and HLA, especially class II rather than class I, and that immunotherapy must be done in case of HLA alleles shared four or more in each couple.
침윤성 복막이식을 동반한 난소의 경계성 표면 유두종 IIIc기 1 예
김흥기,김창이,김수평,김용욱,류순원,전준연,공기환,송영훈 대한산부인과학회 1997 Obstetrics & Gynecology Science Vol.40 No.9
The serous borderline tumors(SBTs) are divided into 3 groups, typical SBT with nonin-vasive implants, SBTs with invasive implants, and a recently described tumor, desinated mic-ropapillary serous carcinoma(MPSC). These tumors are associated with extraovarian implants, espicially peritoneum. Invasiveness of implants has prognostic significance in disease progre-ssion and recurrence. Micropapillary serous carcinoma and SBTs with invasive implants sho-uld be classified as carcinoma and treated accordingly. We report a case of borderline malign-ant ovarian surface papilloma with invasive peritoneal implant.